ARTICLE

Received 7 Jan 2015 | Accepted 20 May 2015 | Published 3 Jul 2015

DOI: 10.1038/ncomms8557

OPEN

Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma

Masafumi Seki^{1,*}, Riki Nishimura^{1,*}, Kenichi Yoshida^{2,3}, Teppei Shimamura^{4,5}, Yuichi Shiraishi⁴, Yusuke Sato^{2,3}, Motohiro Kato^{1,6,7}, Kenichi Chiba⁴, Hiroko Tanaka⁸, Noriko Hoshino⁹, Genta Nagae¹⁰, Yusuke Shiozawa^{2,3}, Yusuke Okuno^{3,11}, Hajime Hosoi¹², Yukichi Tanaka¹³, Hajime Okita¹⁴, Mitsuru Miyachi¹², Ryota Souzaki¹⁵, Tomoaki Taguchi¹⁵, Katsuyoshi Koh⁷, Ryoji Hanada⁷, Keisuke Kato¹⁶, Yuko Nomura¹⁷, Masaharu Akiyama¹⁸, Akira Oka¹, Takashi Igarashi^{1,19}, Satoru Miyano^{4,8}, Hiroyuki Aburatani¹⁰, Yasuhide Hayashi²⁰, Seishi Ogawa^{2,3} & Junko Takita¹

Rhabdomyosarcoma (RMS) is the most common soft-tissue sarcoma in childhood. Here we studied 60 RMSs using whole-exome/-transcriptome sequencing, copy number (CN) and DNA methylome analyses to unravel the genetic/epigenetic basis of RMS. On the basis of methylation patterns, RMS is clustered into four distinct subtypes, which exhibits remarkable correlation with mutation/CN profiles, histological phenotypes and clinical behaviours. A1 and A2 subtypes, especially A1, largely correspond to alveolar histology with frequent *PAX3/7* fusions and alterations in cell cycle regulators. In contrast, mostly showing embryonal histology, both E1 and E2 subtypes are characterized by high frequency of CN alterations and/or allelic imbalances, *FGFR4/RAS/AKT* pathway mutations and *PTEN* mutations/methylation and in E2, also by p53 inactivation. Despite the better prognosis of embryonal RMS, patients in the E2 are likely to have a poor prognosis. Our results highlight the close relationships of the methylation status and gene mutations with the biological behaviour in RMS.

¹Department of Pediatrics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8655, Japan. ²Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan. ³Cancer Genomics Project, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan. ⁴Laboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ⁵Division of Systems Biology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. ⁶Department of Cell Therapy and Transplantation Medicine, The University of Tokyo, Tokyo 113-8655, Japan. ⁷Department of Hematology/Oncology, Saitama Children's Medical Center, Saitama 339-8551, Japan. ⁸Laboratory of Sequence Data Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan. ⁹Department of Pediatric Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-8655, Japan. ¹⁰Genome Science Division, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo 153-8904, Japan. ¹¹Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan. ¹²Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan. ¹³Department of Pathology, Kanagawa Children's Medical Center, Yokohama 232-8555, Japan. ¹⁴Molecular Pathology Laboratory, Department of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan. ¹⁵Department of Pediatric Surgery, Reproductive and Developmental Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan. ¹⁶Division of Pediatric Hematology and Oncology, Ibaraki Children's Hospital, Mito 311-4145, Japan. ¹⁷Department of Pediatrics, School of Medicine, Fukuoka University, Fukuoka 814-0180, Japan. ¹⁸Department of Pediatrics, The Jikei University School of Medicine, Tokyo 105-8471, Japan. ¹⁹National Center for Child Health and Development, Tokyo 157-8535, Japan. ²⁰Department of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Gunma, 377-8577, Japan. * These authors contributed equally to this work. Correspondence and requests for materials should be addressed to S.O. (email: sogawa-tyk@umin.ac.jp) or to J.T. (email: jtakita-tyk@umin.ac.jp).

Rhabdomyosarcoma (RMS), a highly aggressive soft-tissue sarcoma, typically affects children, and it is classified into two major subtypes having alveolar (ARMS) and embryonal (ERMS) histologies^{1,2}. ARMS usually carries specific chromosomal translocations that result in *PAX3*– or *PAX7*–*FOXO1* fusion genes, whereas ERMS commonly harbours loss of heterozygosity at 11p15.5 and gains of chromosomes 2, 8, and 12 in varying combinations^{3,4}. Despite aggressive multimodal therapies, the prognosis of high-risk RMS patients has not been substantially improved, with a 5-year overall survival rate being <20–30%⁵, which prompts a need for new therapeutic strategies targeting molecular pathways that are relevant to the pathogenesis of RMS. In this point of view, recent sequencing studies have revealed a number of recurrent mutational targets of RMS, including multiple components of the *FGFR4/RAS/AKT* pathway, *FBXW7*, *CTNNB1* and *BCOR*^{6,7}. However, the relatively low number of mutations in RMS (12.3/tumor sample⁷) suggests the involvement of other mechanisms, such as epigenetic alterations, which have not been disclosed in the previous studies^{6–8}. To address these issues, we conducted an integrated molecular study in which a cohort of 60 RMSs cases was investigated for somatic mutations, CN alterations, and DNA methylomes using whole-exome/targeted deep sequencing, Single-nucleotide polymorphism (SNP) array-based CN analysis, and Infinium 450 K arrays, respectively. RNA sequencing was also performed for the selected tumours for which high-quality RNA was available (that is, RNA integrity number >6.0). Here we identify novel methylation clusters that exhibit distinct genetic abnormalities, histological subtypes and clinical behaviours, suggesting that aberrant DNA methylation along with genetic alterations is likely to play key roles in the pathogenesis of RMS.

Results

Sequencing and CN analyses of RMS. We first sequenced the exome of 16 paired tumours/normal samples of which 3 were also analysed for relapsed ($n=2$) and metastatic ($n=1$) samples (Supplementary Data 1). The mean coverage was $123\times$, with which 88% of the target exome sequences were analysed at a depth of more than $20\times$ (Supplementary Fig. 1). Among 690-candidate somatic changes detected by our pipeline called Genomon (<http://genomon.hgc.jp/exome/en/index.html>), 604 in 531 genes (88%) were validated by deep sequencing (Supplementary Data 2). The mean numbers of mutation in primary, metastatic, and relapsed tumours were 24.0, 43.3 and 42.0, respectively. Thus, the mutation rate was slightly higher in relapsed/metastatic tumours than in primary tumours, although not statistically significant (primary versus metastasis, t -test $P=0.20$ and primary versus relapsed, $P=0.13$; Supplementary Fig. 2). An excessively high number of somatic mutations was present in one case (RMS_001) in which an *MBD4* gene mutation was implicated in defective DNA repair⁹ (Supplementary Fig. 2). As observed in other cancers, mutations were predominated by C>T/G>A transitions compared with other transitions or transversions¹⁰ (Supplementary Fig. 3).

Among the 531 mutated genes, only 18 were recurrently mutated (Table 1), which not only included known mutational targets in RMS, such as *TP53*, *BCOR*, *KRAS* and other genes in the *FGFR4/RAS/AKT* pathway, but also involved in previously unreported genes, including *ROBO1* and additional *FGFR4/RAS/AKT* pathway genes^{6–8,11}, such as *GAB1* and *PTEN* (Table 1). Thus, to validate the initial observation in the discovery samples and investigate the impact of these mutations on the pathogenesis and clinical outcomes of RMS, we performed follow-up deep sequencing for 14 putative driver genes in the entire cohort of 60

Table 1 | Recurrent mutations in rhabdomyosarcoma cases detected by whole-exome sequencing.

Gene	Location	N	Amino-acid change	Histology	Sample ID
<i>TP53</i>	17p	2	G245S	ERMS	RMS_011M
			C176G	NOS	RMS_012P
<i>GAB1</i>	4q	2	S614R	ARMS	RMS_004R
			N233I	ARMS	RMS_006P
<i>KRAS</i>	12p	2	K117N	ERMS	RMS_014P
			A146T	ERMS	RMS_015P
<i>PTEN</i>	10q	2	G129R	ARMS	RMS_001P
			A120P	ERMS	RMS_009R
<i>ARID1A</i>	1p	2	G1847fs	ARMS	RMS_003R
			K1007_I1008fs	ARMS	RMS_011M
<i>BCOR</i>	Xp	2	S1243fs	ERMS	RMS_014P
			E712fs	Mixed	RMS_017P
<i>ROBO1</i>	3p	2	E1113Q	ARMS	RMS_005P
			Y777C	ARMS	RMS_007P
<i>AKAP9</i>	7q	2	G2652V	ARMS	RMS_001M
			K2673N	ERMS	RMS_009R
<i>DNAH5</i>	5p	2	S2920I	ERMS	RMS_011M
			R3096Q, D3271N	ERMS	RMS_008R
<i>FREM2</i>	13q	2	R1515H	Mixed	RMS_017P
			Q1574L	ERMS	RMS_008R
<i>C15orf2</i>	15q	2	G917A	ARMS	RMS_003P
			V1147L	ERMS	RMS_009R
<i>KIF21A</i>	12q	2	E766V	Mixed	RMS_017P
			L956P	ERMS	RMS_009R
<i>NEB</i>	2q	2	E637Q	ARMS	RMS_001P
			D1595Y	ARMS	RMS_003P
<i>PTPRO</i>	12p	2	R67T	ARMS	RMS_002R
			N644S	Mixed	RMS_017P
<i>COL5A2</i>	2q	2	G203V	ARMS	RMS_001P
			G756S	ARMS	RMS_002P
<i>PXDNL</i>	8q	2	T877M	ARMS	RMS_004R
			R1225Q	ARMS	RMS_016M
<i>NLRCS</i>	16q	2	R341W	ARMS	RMS_003P
			Q1169H	ARMS	RMS_001P
<i>TTN</i>	2q	4	L18955Q, L18955I	ARMS	RMS_001M
			G17007A	ARMS	RMS_004R
			E5800A	ERMS	RMS_009P
			Q9568K	ARMS	RMS_017P

ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, not otherwise specified.

RMS cases including the 16 discovery cases (Supplementary Data 3). Overall, 56 mutations were found in the 14 genes (Table 2, Supplementary Data 4, Supplementary Fig. 4). The most frequently mutated genes were *TP53* (9/60; 15.0%) and *FGFR4/RAS/AKT* pathway genes (24/60; 40%), which were predominantly detected in ERMS tumours⁷ (Fig. 1, Table 2). Among *FGFR4/RAS/AKT* pathway mutations, RAS pathway genes were mutated in 15 cases, in which all mutations in *NRAS/KRAS/HRAS* ($n=10$) and *PTPN11* ($n=2$) occurred in hot-spot amino acids involved in gene activation, whereas three of four *NF1* mutations were frameshift indels resulting in premature truncation of the protein. Five of six *FGFR4* mutations affected highly conserved amino acids within the kinase domain of which four were previously reported activating mutations¹¹, N535K and V550L. Additional four mutations involved *PIK3CA*, which have previously been reported in other cancers, are thought to be activating in nature^{12–14}. Other commonly mutated genes were *BCOR* and *ARID1A*. All *BCOR* mutations and four of six *ARID1A* mutations were frameshift or nonsense mutations, suggesting the importance of inactivation of these genes in the pathogenesis of RMS.

A number of genes and pathways were also recurrently affected by CN alterations and thought to be implicated in deregulated

Table 2 | Detected mutations in 60 rhabdomyosarcoma cases by targeted deep sequencing.

	All (%) n = 60	Histology					Fusion status		Methylation cluster				
		ERMS (%) n = 35	ARMS (%) n = 22	Mixed (%) n = 1	NOS (%) n = 1	U (%) n = 1	FP (%) n = 19	FN (%) n = 41	E1 (%) n = 11	E2 (%) n = 11	A1 (%) n = 18	A2 (%) n = 10	NA (%) n = 10
FGFR4/RAS/AKT pathway total	24* (40)	16 (46)	7 (32)	1 (100)	0 (0)	0 (0)	3 (16)	21 (51)	6 (55)	9 (82)	3 (17)	2 (20)	4 (40)
FGFR4	5 (8.3)	5 (14)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	5 (12)	0 (0)	4 (36)	0 (0)	0 (0)	1 (10)
PTPN11	2 (3.3)	2 (5.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.9)	0 (0)	2 (18)	0 (0)	0 (0)	0 (0)
GAB1	3 (5.0)	1 (2.9)	2 (9.1)	0 (0)	0 (0)	0 (0)	1 (5.3)	2 (4.9)	0 (0)	0 (0)	2 (11)	0 (0)	1 (10)
PIK3CA	3 (5.0)	2 (5.7)	1 (4.5)	0 (0)	0 (0)	0 (0)	1 (5.3)	2 (4.9)	0 (0)	2 (18)	0 (0)	0 (0)	1 (10)
PTEN	2 (3.3)	1 (2.9)	1 (4.5)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.9)	0 (0)	1 (9.1)	1 (5.6)	0 (0)	0 (0)
HRAS	1 (1.7)	0 (0)	1 (4.5)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.4)	0 (0)	0 (0)	0 (0)	1 (10)	0 (0)
KRAS	2 (3.3)	2 (5.7)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4.9)	2 (18)	0 (0)	0 (0)	0 (0)	0 (0)
NRAS	7 (12)	5 (14)	2 (9.1)	0 (0)	0 (0)	0 (0)	1 (5.3)	6 (15)	2 (18)	2 (18)	1 (5.6)	0 (0)	2 (20)
NF1	3 (5.0)	2 (5.7)	0 (0)	1 (100)	0 (0)	0 (0)	0 (0)	3 (7.3)	1 (9.1)	2 (18)	0 (0)	0 (0)	0 (0)
TP53	9 (15)	6 (17)	1 (4.5)	0 (0)	1 (100)	1 (100)	1 (5.3)	8 (20)	0 (0)	5 (45)	2 (11)	1 (10)	1 (10)
FBXW7	1 (1.7)	1 (2.9)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2.4)	0 (0)	1 (9.1)	0 (0)	0 (0)	0 (0)
BCOR	5 (8.3)	4 (11)	0 (0)	1 (100)	0 (0)	0 (0)	1 (5.3)	4 (9.8)	3 (27)	1 (9.1)	1 (5.6)	0 (0)	1 (10)
ARID1A	6 (10)	4 (11)	2 (9.1)	0 (0)	0 (0)	0 (0)	1 (5.3)	5 (12)	0 (0)	3 (27)	1 (5.6)	0 (0)	2 (20)
ROBO1	2 (3.3)	0 (0)	2 (9.1)	0 (0)	0 (0)	0 (0)	2 (11)	0 (0)	0 (0)	0 (0)	1 (5.6)	0 (0)	1 (10)

ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, RMS not otherwise specified; U, unknown; FP, fusion positive; FN, fusion negative; NA, not available.
*4 cases had 2 mutations in *FGFR4/RAS/AKT* pathway genes.

FGFR4/RAS/AKT signalling (focal amplification of *FRS2* at 12q15; 12%) and cell cycle regulation (focal amplification of *MYCN* at 2p24.3, loss of *CDKN2A/B* at 9p21, *TP53* at 17p13.2, and *MDM2* at 12q15; Figs 1 and 2, Supplementary Fig. 5). Other genes displaying significant CN alterations included *ALK* (2p23.2) and *STAT6* (12q13.3) (Supplementary Data 5 and 6). As previously reported, the ARMS-related fusion genes *PAX3/7* ($n=6$) and *FOXO1* ($n=6$) were frequently accompanied by local amplifications^{15,16}.

Transcriptome analysis of RMS. Fusion transcripts were investigated by RNA sequencing in eight cases of RMS, including five ERMS and three ARMS cases (Supplementary Data 1). In total, we identified 22 fusion transcripts, of which three were predicted to be in-frame, whereas the remaining 19 were out-of-frame

fusions. Expression of fusion transcripts was confirmed by reverse transcription-PCR (RT-PCR) for 2 in-frame and 10 out-of-frame fusions (Supplementary Data 7), but no recurrent fusions were identified, except for the *PAX3-FOXO1* fusion found in two cases of ARMS. The *NSD1-ZNF346* fusion that was previously identified in an ERMS cell line⁶, was found in a case of ERMS. However, the *NSD1-ZNF346* fusion detected in our study was out-of-frame and thus functional significance of this fusion transcript is still elusive.

Novel clusters identified by DNA methylation analysis. To further explore the molecular basis of RMS, we investigated genome-wide DNA methylation in 53 RMS tumours using Infinium HumanMethylation450 BeadChip (Illumina). DNA methylation profiling based on unsupervised hierarchical

Figure 2 | Significant copy-number (CN) alterations detected in rhabdomyosarcoma. (a) Statistically significant CN gains and losses detected by the GISTIC algorithm are shown in the left and right boxes, respectively. For each q -value peak, the putative gene targets are listed. A dashed line represents the centromere of each chromosome. Red and blue lines indicate the q -value for gains and losses, respectively. (b–h) Heatmaps of significant CN alterations are shown for gene targets at 1p36.13 (b), 2p24.3 (c), 2q36.1 (d), 12q15 (e), 13q14.1 (f), 9p21.1 (g) and 17p13.1 (h).

clustering identified four unique clusters having distinct methylation signatures (Fig. 3a), and the microarray data were validated by bisulfite sequencing for selected probes ($n=160$; Supplementary Fig. 6). Remarkably, we found that these clusters correlated with histological subtypes, genetic abnormalities and clinical outcomes. Two clusters, E1 and E2, were composed almost exclusively of ERMS (95.5%; Fig. 3a), whereas all cases of ARMS were grouped into the two remaining clusters A1 and A2 (Fig. 3a). Accordingly, all tumours positive for *PAX3-FOXO1* or *PAX7-FOXO1* fusions were grouped into the A1/A2 clusters, although the separation between A1 and A2 did not coincide with the presence or absence of fusions (Fig. 3a). In our analysis, 29 genes were significantly hypermethylated in the E1/E2 clusters

compared with the A1/A2 clusters. On the other hand, only 10 genes were significantly hypermethylated in the A1/A2 clusters compared with those in the E1/E2 cluster (Fig. 3b; Supplementary Fig. 7; Supplementary Data 8). Among these, the largest extent of promoter methylation was observed in *PTEN* in the clusters E1/E2 and *GATA4* in the clusters A1/A2. Of note, we found an extremely high frequency of *PTEN* hypermethylation in E1/E2 tumours (20 of 22; 90.9%), whereas only two of 28 (7.1%) in A1/A2 tumours showed *PTEN* hypermethylation (Fig. 3c). Subsequent quantitative RT-PCR analysis revealed that *PTEN* hypermethylation was significantly associated with the absence of *PTEN* expression, suggesting that epigenetic silencing of *PTEN* is a representative mechanism of E1/E2 tumours ($P=0.045$; Supplementary Fig. 8). *GATA4* encodes a member of the GATA family of transcription factors^{17,18} and has been shown to be methylated in a subset of RMS cases¹⁹. However, because *GATA4* expression is limited to the heart, testis and ovary, significance of methylation in RMS pathology is still unclear. We also found 23 genes significantly hypermethylated in E2 compared with E1 and 25 genes in A1 to A2 (Supplementary Fig. 9, Supplementary Data 9 and 10). Although these findings should be validated in independent samples, methylation of these genes could be potentially used for discriminating these subtypes.

Figure 3 | Hierarchical clustering of DNA methylation profiles and significant *PTEN* hypermethylation in cluster E1/E2. (a) The heatmap shows the DNA methylation profiles of 53 rhabdomyosarcoma (RMS) tumours based on unsupervised hierarchical clustering. Tumours were hierarchically clustered into four subgroups: E1, E2, A1 and A2. Clusters E1 and E2 were composed almost exclusively of embryonal RMS (95.5%), whereas all alveolar RMS were classified into clusters A1/A2. Red, high methylation; blue, low methylation. (b) Volcano plot comparing the number of significantly hypermethylated probes between clusters E1/E2 and A1/A2. Significantly hypermethylated probes showing >2 -fold change are coloured in orange ($P < 1.0 \times 10^{-8}$, Wilcoxon's rank-sum test). Red dots represent significantly hypermethylated probes in the promoter regions of *PTEN* in cluster E. (c) Difference in *PTEN* methylation intensities between clusters E1/E2 and A1/A2. Significantly higher methylation intensities were observed in cluster E1/E2 than in cluster A1/A2. The P -value was calculated using the Wilcoxon rank-sum test. β -values represent significantly hypermethylated eight promoter-associated probes (red dots in the Volcano plot) of *PTEN*. For the box and whisker plots, the bottom and top of the box are the first and third quartiles, the line inside the box is the median and the whiskers extend up to 1.5 times the interquartile range.

Characteristics of the methylation subgroups in RMS. To obtain a better understanding of DNA methylation in each subgroup, we further performed Ingenuity pathway analysis (<http://www.ingenuity.com/>) using probe lists of E1/E2 versus A1/A2, E1 versus E2 and A1 versus A2 (Supplementary Data 8–10). However, relevant cancer-associated pathways in the pathogenesis of RMS were not detected in the A1/A2 and E1/E2 subgroups (Supplementary Data 11 and 12). A functional annotation named 'abnormal morphology of muscle,' containing *DYSF*, *ELN*, *OTX2* and *TH*, was detected as a significantly hypermethylated component in A1 compared with A2 ($P = 6.2 \times 10^{-4}$; Supplementary Data 13–16). In addition, the promoter of *P4HMT*, the family of prolyl 4-hydroxylases, was significantly hypermethylated in E2 compared with E1 ($P = 0.035$; Supplementary Fig. 9). Intriguingly, *P4HMT* hypermethylation was also reported in a previous study regarding DNA promoter methylation in 10 RMS tumours¹⁹. However, the biological significance of these genes in the pathogenesis of RMS is still unclear.

Next, we analysed the genetic and clinical characteristics of each methylation subgroup. E1 tumours showed a lower mutation rate (mean, 20.0/sample) than E2 tumours (mean, 45.0/sample), although not statistically significant ($P = 0.084$). Compared with the A1/A2 clusters, the E1/E2 clusters were characterized by high frequencies of multiple chromosomal CN changes including gains of chromosomes 2, 8 or 12 ($P = 5.2 \times 10^{-4}$). In addition, the mutation frequency of the *FGFR4/RAS/AKT* pathway was much higher in the E1/E2 clusters than in the A1/A2 clusters ($P = 4.6 \times 10^{-4}$), and these mutations were predominantly observed in the E2 cluster (54.5% in E1 and 81.8% in E2 versus 17.9% in A1/A2; Fig. 4; Table 2). Among the *FGFR4/RAS/AKT* pathway mutations, mutations in *FGFR4*, *PTPTN11* and *PIK3CA* frequently occurred in E2 compared with E1 ($P = 1.0 \times 10^{-3}$). Furthermore, E2 tumours had significantly frequent *TP53* mutations (45.5%) compared with E1 tumours (0%; $P = 0.035$). In contrast, mutations and CN alterations affecting cell cycle regulators, such as *MYCN*, *CDK4* and *CDKN2A/B*, except for *MDM2*, were particularly enriched in the A1/A2 clusters compared with the E1/E2 clusters ($P = 0.016$), suggesting that these genes may have driver roles in A1/A2 tumours.

Finally, patients in the E2 cluster displayed significantly worse overall survival than those in the E1 cluster, regardless of stage,

Figure 4 | Correlations between DNA methylation clusters and additional parameters. (a) Integrated view of DNA methylation clusters combined with histology, outcome, fusion status, gene alterations and copy-number changes. The horizontal axis represents each tumor. ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; NOS, not otherwise specified; Mut, mutation; Met, methylation; CNA, copy-number alteration; Hetero., heterozygous; Com. Hetero., compound heterozygous mutation; CN, copy number; LOH, loss of heterozygosity; N, *NRAS*; K, *KRAS*; H, *HRAS*; P, detected in primary sample alone; R, Detected in relapse sample alone; F, *PAX3-FOXO1* fusion-positive ERMS. (b) Kaplan-Meier curves of overall survival for each DNA methylation cluster. The *P*-value of the log-rank test is shown.

age and the site of tumour involvement ($P = 0.045$; Fig. 4b). In addition, among commonly mutated genes and pathways, only *TP53* mutations but not *FGFR4/RAS/AKT* pathway mutations (including *FGFR4*, *PTPN11*, *PIK3CA* and *PTEN* mutations) significantly affected the overall survival of E1/E2 patients ($P = 2.9 \times 10^{-3}$). However, the impact of the E1/E2 classification on overall survival was more prominent than that of the *TP53* mutations (Supplementary Fig. 10). These results suggest that the methylation status that defines the E1/E2 clusters might be a predictor of overall survival, independent of gene mutations.

Discussion

Our sequencing screen identified both previously well-recognized gene mutations including *FGFR4/RAS/AKT* pathway mutations and novel recurrently mutated genes, such as *PTEN*, *GAB1* and *ROBO*. Most *FGFR4/RAS/AKT* pathway alterations, excluding *GAB1*, were predominantly found in ERMS (Fig. 1), suggesting that deregulated *FGFR4/RAS/AKT* signalling plays an important role in the pathogenesis of ERMS. Because the *PTEN* missense mutation affecting G129 has been reported in several cancers^{20,21} and is thought to abrogate most *PTEN* activity, the *PTEN* G129R mutation detected in RMS should have an oncogenic effect. The allele frequency of the *PTEN* A120P mutation was 0.84, and in accordance with this finding, the SNP array analysis disclosed uniparental disomy involving the *PTEN* locus by which the mutated allele was duplicated. Thus, the A120P substitution is likely to be an oncogenic mutation rather than a non-functional SNP. Although somatic mutations in *GAB1* and *ROBO1* have been reported in several cancers, the role of these genes in the RMS pathogenesis is unknown^{22–24}.

Probably, the most significant finding in the current study would be the identification of the novel methylation clusters, which tightly correlated with genetic abnormalities, histological subtypes and clinical behaviours, underscoring the importance of integrated molecular analyses. Importantly, this finding revealed an otherwise unrecognizable subset of ERMS that showed a poor prognosis (E2 cluster) for which intensification or novel therapeutic approaches need to be considered. We also found an extremely high frequency of epigenetic silencing of *PTEN* in ERMS. *PTEN* is one of the most frequently mutated tumour suppressors in human cancers and is also essential for embryonic

development²⁵. *PTEN* modulates G1 cell cycle progression by negatively regulating the *FGFR4/PI3K/AKT* axis. Thus, the finding that *PTEN* methylation/mutation is highly specific to and frequent in the E1/E2 tumours indicates that *PTEN* may serve as a diagnostic marker to identify those patients for which inhibition of the *FGFR4/PI3K/AKT* axis could have a key therapeutic role. Finally, the biological/genetic basis for these distinct methylation clusters, nevertheless, is currently unknown and it should be addressed in future studies. Since our single cohort in the current study is very limited, to provide an adequate assessment of molecular subgroups, more large number of independent cohorts should be evaluated.

Methods

Samples. This study cohort comprised 66 tumours from 60 cases with RMS (22 ARMS, 35 ERMS, one mixed type, one RMS, not otherwise specified, and one unknown histology. Matched normal specimens (mononuclear cells from peripheral blood or bone marrow at diagnosis or in remission) were available in 16 cases, which were subjected to whole-exome sequencing. In three ARMS cases, samples from both primary and recurrent or metastatic tumours were available, which were analysed by whole-exome sequencing. Detailed information on subjects and samples is provided in Supplementary Data 1 and 3. To generate sufficient DNA templates of tumour and germline DNA in a subset of cases in which enough samples were not available, whole-genome amplification was performed using the REPLI-g kit (Qiagen). The amplified DNAs were used in part for targeted deep sequencing to validate individual candidate mutations detected in whole-exome sequencing; to analyse all coding sequences of possible candidate genes in the validation cohort. Written informed consent for research use was obtained from patients' parents, and this study was approved by the Human Genome, Gene Analysis Research Ethics Committee of the University of Tokyo.

Whole-exome sequencing. In 19 samples from 16 cases, whole-exome capture libraries were constructed from tumour and matched normal DNA using Agilent SureSelect Human All Exon 50 Mb, V4 or V5 (Agilent Technologies) according to the manufacturer's protocol. Enriched exome libraries were sequenced with the HiSeq 2,000 platform (Illumina). For identifying candidates for somatic mutations from exome-sequencing data, the ECall (Empirical Bayesian mutation calling)²⁶ algorithm was used. This algorithm discriminates somatic mutations from sequencing errors based on an empirical Bayesian method using sequencing data of multiple non-paired germline samples.

RNA sequencing. In eight tumour samples from our RMS which high-quality RNA (that is, RNA integrity number > 6.0) was available, RNA sequencing was performed using HiSeq 2,000. RNA sequencing libraries were prepared using the Truseq RNA Sample Preparation kit (Illumina). Candidates of fusion transcripts were identified using Genomon-fusion. All candidates of gene fusion, which represented more than two paired-reads were subjected to confirm by RT-PCR-

based Sanger sequencing. The primer sets used for RT-PCR analysis were listed in Supplementary Data 7.

Validation of putative somatic variants. To validate putative genomic variants detected in whole-exome sequencing, targeted deep sequencing was performed²⁷. Regions encompassing possible variations were amplified with *NotI*-tagged primers. Pooled PCR amplicons were digested with *NotI*, followed by ligation with T4 DNA ligase. Ligated PCR amplicons were sonicated into fragments of an average size of 200 bp using a Covaris sonicator. After being enriched and multiplexed, the prepared libraries were subjected to deep sequencing using Illumina HiSeq 2,000 or MiSeq with a 100-bp or 150-bp pair-end reads option. Both tumour and germline DNA were examined to confirm somatic variations. Selective variants of which PCR primers could be constructed by Primer 3^{28,29} were subjected to deep sequencing for validation. The validated mutations are listed in Supplementary Data 2.

Evaluation of mutation candidates. For 14 candidate genes, including recurrent mutated genes in exome sequencing (*TP53*, *BCOR*, *ARID1A*, *GAB1*, *ROBO1*, *PTEN* and *KRAS*), and the associated genes (*FGFR4*, *PIK3CA*, *HRAS*, *NRAS*, *PTPN11*, *NF1* and *FBXW7*), PCR-based deep sequencing of the candidate genes was performed in 66 samples using HiSeq 2000 or MiSeq (Illumina). *NotI*-tagged primers (Supplementary Data 17) were used to generate each PCR amplicon. Selected exons were sequenced for *FGFR4*, *PIK3CA* and *PTPN11*. Sample preparation, data processing and variant detection were performed as described above in the methods section of Validation of putative somatic variants.

DNA methylation analysis. In 53 RMS samples from 50 cases, comprehensive DNA methylation analysis was performed with the Infinium HumanMethylation450 BeadChip (Illumina) according to the manufacturer's protocol. Beta-values were converted to *M*-values³⁰, then *pcaMethods* bioconductor R package was used to impute incomplete data. *M*-values were converted to beta-values again and imputed beta-values were used for further analysis. To determine the DNA methylation profiles, the following steps were adopted to select probes for unsupervised clustering analysis. We first removed probes that were designed for sequences on the X and Y chromosomes. Second, we selected probes with variance ranked in the top 1% of the remaining probes. We then performed unsupervised hierarchical clustering with 4,708 probes, identifying 4 distinct clusters. To detect methylation status compared with normal skeletal muscles, published data of the same 450 k platform was used³¹. Wilcoxon rank-sum test was performed to select differentially methylated probes. To detect differentially methylated genes for each sample, multiplicative decomposition model of gene methylation was adopted. Let x_{ijk} be the beta value at probe location j within 1,500 bps of the transcription start site of gene k for RMS sample i , c_{jk} be the average beta value at the same location of the same gene for 48 normal skeletal muscle samples, n be the number of samples, g be the number of genes, and p_k be the number of probes within 1,500 bps of transcription start site of gene k . For each gene k , we consider a following multiplicative model of the two-way table of gene methylation changes:

$$x_{ijk} = a_{ik} \times b_{jk} + c_{jk} + e_{ijk}, \quad (1)$$

where e_{ijk} is an observation error, a_{ik} is the methylation pattern depending on sample i , and b_{jk} is the methylation pattern depending on probe location j , respectively. The parameters a_{ik} , $i = 1, \dots, n$ and b_{jk} , $j = 1, \dots, p_k$ are estimated by Bayesian principal component analysis³². The signs of a_{ik} , $i = 1, \dots, n$ are chosen so that they are proportional to the average beta value of p_k locations of gene k . The *z*-score to see if a_{ik} is significantly larger or smaller than those of the normal skeletal muscles is then calculated by:

$$z_{ik} = \frac{a_{ik} - \bar{a}_k}{\sigma_k}, \quad (2)$$

where $\bar{a}_k$ and σ_k are the average and s.d. of the sample-dependent methylation patterns for the normal skeletal muscles, respectively.

For a given threshold T , we can declare the methylation status of gene k for sample i to be an aberration compared with that of normal skeletal muscles if $|z_{ik}| > T$. Here identifying aberrations can be thought of as a multiple-testing problem where we are testing the following hypothesis for each gene within each sample:

$$H_0(i, k) = \text{no aberration of gene } k \text{ for sample } i. \quad (3)$$

An estimator of the false discovery rate³³ for threshold T can be calculated by

$$\widehat{FDR}(T) = \frac{\sum_{i=1}^n \sum_{k=1}^g I(|z_{ik}| > T) I(H_0(i, k) \text{ is true})}{\sum_{i=1}^n \sum_{k=1}^g I(|z_{ik}| > T)}. \quad (4)$$

The threshold T is then chosen so that $\widehat{FDR}(T) < 0.001$.

Quantitative RT-PCR. Quantitative RT-PCR for *PTEN* was performed in 19 samples from which enough RNA was available. RNA (200 ng) extracted from the fresh-frozen tumours were subjected to reverse transcription using the SuperScript VILO MasterMix (Invitrogen) according to the manufacturer's protocol.

Quantitative mRNA expression levels were measured using the QuantiTect SYBR Green PCR kit (Qiagen, Tokyo, Japan) with an iCycler iQ real-time PCR detection system (Bio-Rad). The optional thermal-cycling condition was as follows: 40 cycles of a two-step PCR (95 °C for 15 s, 58 °C for 60 s) after the initial denaturation (95 °C for 10 min). For the purpose of normalization, relative expression levels were calculated by dividing the expression level of the respective gene by that of GAPDH³⁴. Primers used for quantitative RT-PCR are listed in Supplementary Data 18.

Bisulfite conversion and bisulfite sequencing of *PTEN*. To confirm *PTEN* methylation, bisulfite sequencing using nested primers was performed. Genomic DNA (500 ng) was bisulfite-modified using the EpiTect Plus DNA Bisulfite Kit (Qiagen) according to the manufacturer's instructions. Primer sequences for PCR amplicons are listed in Supplementary Data 18. Complete bisulfite modification was confirmed by bisulfite sequence analysis of the replicated normal DNA.

Bisulfite sequencing for validation of methylation array. To validate the result of DNA methylation array, targeted bisulfite deep sequencing was performed. Five samples among each cluster were randomly selected for validation. As positive controls, two samples of replicated normal DNA were also analysed by bisulfite sequencing. Genomic DNA (1,000 ng) was bisulfite modified using the EpiTect Plus DNA Bisulfite Kit (Qiagen) according to the manufacturer's instructions. Among extracted 266 probes (E1/E2 versus A1/A2, E1 versus E2 and A1 versus A2), we selected probes to validate, which recurrently detected in three or more. Finally, 160 probes were subjected to target deep sequencing. Bisulfite PCR was performed in 22 samples (20 tumours and two controls) with *NotI*-tagged primers as described above. For data analysis, the same method of targeted deep sequencing was used, with modified mapping to bisulfite converted reference genome. Methylated cytosine was calculated as variant allele frequency. Validated probes were listed in Supplementary Data 19. The Spearman correlation coefficient was used to compare beta-values and methylated allele frequencies.

Pathway analysis. Ingenuity pathway analysis (<http://www.ingenuity.com/>) was performed for extracted genes listed in Supplementary Data 8–10.

SNP array analysis. DNA extracted from RMS samples was subjected to SNP array analysis using Affymetrix GeneChip 250K *Nsp* or CytoScan HD (Affymetrix) according to the manufacturer's protocol. Details regarding the use of these platforms are listed in Supplementary Data 1 and 3. CNAG/AsCNAR software was used for subsequent informatics analysis for SNP array data, which enables accurate detection of allelic status without paired normal DNA, even in the presence of up to 70–80% normal cell contamination^{35,36}. Significant focal CN alterations were identified using GISTIC 2.0³⁷ for 250 k array data. The array data have been partially published in the previous our paper³.

Analyses of *PAX* gene fusions. The status of the *PAX3/7-FOXO1* fusion gene was examined by RT-PCR followed by Sanger sequencing in 34 tumours for which RNA or cDNA was available. The primers and the PCR condition are listed in Supplementary Data 20.

Statistical analysis. Fisher's exact test was used to evaluate the differences in chromosomal CN changes between ARMS and ERMS or the correlation between CN changes and prognosis in each subgroup. The numbers of mutations or CN changes were compared by *t*-test.

References

- Ognjanovic, S., Linabery, A.M., Charbonneau, B. & Ross, J.A. Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975–2005. *Cancer* **115**, 4218–4226 (2009).
- Malempati, S. & Hawkins, D.S. Rhabdomyosarcoma: review of the Children's Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studies. *Pediatr. Blood Cancer* **59**, 5–10 (2012).
- Nishimura, R. *et al.* Characterization of genetic lesions in rhabdomyosarcoma using a high-density single nucleotide polymorphism array. *Cancer Sci.* **104**, 856–864 (2013).
- Liu, C. *et al.* Analysis of molecular cytogenetic alteration in rhabdomyosarcoma by array comparative genomic hybridization. *PLoS ONE* **9**, e94924 (2014).
- Breneman, J.C. *et al.* Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma—a report from the Intergroup Rhabdomyosarcoma Study IV. *J. Clin. Oncol.* **21**, 78–84 (2003).
- Chen, X. *et al.* Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer cell* **24**, 710–724 (2013).
- Shern, J.F. *et al.* Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. *Cancer Discov.* **4**, 216–231 (2014).

8. Kohsaka, S. *et al.* A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. *Nature Genet.* **46**, 595–600 (2014).
9. Bellacosa, A. Role of MED1 (MBD4) Gene in DNA repair and human cancer. *J. Cell Physiol.* **187**, 137–144 (2001).
10. Alexandrov, L.B. *et al.* Signatures of mutational processes in human cancer. *Nature* **500**, 415–421 (2013).
11. Vi, J.G.T. *et al.* Identification of FGFR4 -activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models. *J. Clin. Invest.* **119**, 3395–3407 (2009).
12. Samuels, Y. *et al.* High frequency of mutations of the PIK3CA gene in human cancers. *Science* **304**, 554 (2004).
13. Campbell, I.G. *et al.* Mutation of the PIK3CA gene in ovarian and breast cancer. *Cancer Res.* **64**, 7678–7681 (2004).
14. Rosty, C. *et al.* PIK3CA activating mutation in colorectal carcinoma: associations with molecular features and survival. *PLoS ONE* **8**, e65479 (2013).
15. Barr, F.G. *et al.* In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma. *Hum. Mol. Genet.* **5**, 15–21 (1996).
16. Weber-Hall, S. *et al.* Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma. *Genes Chromosomes Cancer* **17**, 7–13 (1996).
17. Laverriere, A. C. *et al.* GATA-4/5/6, a subfamily of three transcription factors transcribed in developing heart and gut. *J. Biol. Chem.* **269**, 23177–23184 (1994).
18. Molkentin, J.D. The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. *J. Biol. Chem.* **275**, 38949–38952 (2000).
19. Mahoney, S.E., Yao, Z., Keyes, C.C., Tapscott, S.J. & Diode, S.J. Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. *Epigenetics* **7**, 400–408 (2012).
20. Li, J. *et al.* PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. *Science* **275**, 1943–1947 (1997).
21. Wang, S.I. *et al.* Somatic mutations of PTEN in glioblastoma multiforme. *Cancer Res.* **57**, 4183–4186 (1997).
22. Sjöblom, T. *et al.* The consensus coding sequences of human breast and colorectal cancers. *Science* **314**, 268–274 (2006).
23. Ortiz-Padilla, C. *et al.* Functional characterization of cancer-associated Gab1 mutations. *Oncogene* **32**, 2696–2702 (2013).
24. Biankin, A.V. *et al.* Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. *Nature* **491**, 399–405 (2012).
25. Yamada, K.M. & Araki, M. Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. *J. Cell Sci.* **114**, 2375–2382 (2001).
26. Shiraishi, Y. *et al.* An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. *Nucleic Acids Res.* **41**, e89–e89 (2013).
27. Yoshida, K. *et al.* Frequent pathway mutations of splicing machinery in myelodysplasia. *Nature* **478**, 64–69 (2011).
28. Untergasser, A. *et al.* Primer3—new capabilities and interfaces. *Nucleic Acids Res.* **40**, e115–e115 (2012).
29. Koressaar, T. & Remm, M. Enhancements and modifications of primer design program Primer3. *Bioinformatics* **23**, 1289–1291 (2007).
30. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. *BMC Bioinformatics* **11**, 587 (2010).
31. Zykovich, A. *et al.* Genome-wide DNA methylation changes with age in disease-free human skeletal muscle. *Aging Cell* **13**, 360–366 (2014).
32. Oba, S. *et al.* A Bayesian missing value estimation method for gene expression profile data. *Bioinformatics* **19**, 2088–2096 (2003).
33. Klipper-Aurbach, Y. *et al.* Mathematical formulae for the prediction of the residual beta cell function during the first two years of disease in children and adolescents with insulin-dependent diabetes mellitus. *Med. Hypotheses* **45**, 486–490 (1995).
34. Takita, J. *et al.* Aberrations of NEGR1 on 1p31 and MYEOV on 11q13 in neuroblastoma. *Cancer Sci.* **102**, 1645–1650 (2011).
35. Nannya, Y. *et al.* A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. *Cancer Res.* **65**, 6071–6079 (2005).
36. Yamamoto, G. *et al.* Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. *Am. J. Hum. Genet.* **81**, 114–126 (2007).
37. Mermel, C.H. *et al.* GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol.* **12**, R41–R41 (2011).

Acknowledgements

We are grateful to Ms Matsumura, Ms. Hoshino, Ms Yin, Ms Saito, Ms Mori and Ms Ogino for their excellent technical assistance. We also wish to express our appreciation to Dr M-J. Park, Gunma Children's Medical Hospital and Dr Y. Arakawa, Saitama Children's Medical Hospital, for collecting samples. This work was supported by KAKENHI (25253095 and 26293242) of Japan Society of Promotion of Science; Research on Measures for Intractable Diseases, Health, and Labor Sciences Research Grants, Ministry of Health, Labor and Welfare; by Research on Health Sciences focusing on Drug Innovation; by the Japan Health Sciences Foundation; by Core Research for Evolutional Science and Technology, Japan Science and Technology Agency; and by The Project for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (886695).

Author contributions

M.S., R.N., N.H. and K.Y. performed DNA sequencing. Y.Shiraishi, T.S., K.C., H.T., Y.Shiozawa, Y.O. and S.M. performed bioinformatics analyses of the sequencing data. R.N., Y.Sato and M.K. performed SNP array analysis. M.S., T.S., G.N. and H.A. performed methylation analysis. M.K., H.H., Y.T., H.O., M.M., R.S., T.T., K.Koh, R.H., K.Kato, Y.N., M.A. and Y.H. provided specimens and were also involved in planning the project. M.S., K.Y., K.M., S.O. and J.T. generated figures, tables and supplementary information. M.S., S.O. and J.T. wrote the manuscript and A.O., T.I., Y.H., S.O. and J.T. edited the main text and figures. S.O. and J.T. led the entire project. All authors participated in the discussion and interpretation of data and results.

Additional information

Accession codes: Whole-exome sequence data and the methylation microarray data has been deposited in the European Nucleotide Archive, hosted by the European Bioinformatics Institute, under the accession code EGAS00001000884. The SNP array data have been deposited in the Gene Expression Omnibus under accession number GSE41263 and GSE63891.

Supplementary Information accompanies this paper at <http://www.nature.com/naturecommunications>

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at <http://npg.nature.com/reprintsandpermissions/>

How to cite this article: Seki, M. *et al.* Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. *Nat. Commun.* **6**:7557 doi: 10.1038/ncomms8557 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>